| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Biological Sciences, Allergan Inc., Irvine, California.
PURPOSE. To determine, using electrophysiological measures of visual system function, whether oral daily dosing of memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates.
METHODS. Argon laser treatment of the anterior chamber angle was used to induce chronic ocular hypertension (COHT) in the right eye of 18 macaque monkeys. Nine animals were orally dosed daily with 4 mg/kg memantine while the other nine animals received an oral dose of vehicle only. Using both conventional and multifocal methods, recordings of the electroretinogram (ERG) were made at approximately 3, 5, and 16 months after elevation of the intraocular pressure (IOP). Recordings of the visually-evoked cortical potential (VECP) were also made at the 16-month time point.
RESULTS. Chronic ocular hypertension was associated with a reduction in the amplitude of components of the multifocal ERG response and visually-evoked cortical potential. Memantine-treated animals suffered less amplitude reduction for these measures than did vehicle-treated animals, though this treatment effect on the ERG measures was observed only at the early time points (3 and 5 months post IOP elevation). Memantine treatment was not associated with an effect on either the kinetics or amplitude of ERG or VECP response measures obtained from the normotensive eyes.
CONCLUSIONS. Systemic treatment with memantine, a compound which does not lower intraocular pressure, was both safe and effective for reduction of functional loss associated with experimental glaucoma.
This article has been cited by other articles:
|
|
 |
|
  C.-J. Dong, Y. Guo, P. Agey, L. Wheeler, and W. A. Hare {alpha}2 Adrenergic Modulation of NMDA Receptor Function as a Major Mechanism of RGC Protection in Experimental Glaucoma and Retinal Excitotoxicity Invest. Ophthalmol. Vis. Sci., October 1, 2008; 49(10): 4515 - 4522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Fan, X. Li, and N. G. F. Cooper CaMKII{alpha}B Mediates a Survival Response in Retinal Ganglion Cells Subjected to a Glutamate Stimulus Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3854 - 3863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Harwerth, A. S. Vilupuru, N. V. Rangaswamy, and E. L. Smith III The Relationship between Nerve Fiber Layer and Perimetry Measurements Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 763 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. He, B. V. Bui, and A. J. Vingrys The Rate of Functional Recovery from Acute IOP Elevation Invest. Ophthalmol. Vis. Sci., November 1, 2006; 47(11): 4872 - 4880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Guo, T. E. Salt, A. Maass, V. Luong, S. E. Moss, F. W. Fitzke, and M. F. Cordeiro Assessment of Neuroprotective Effects of Glutamate Modulation on Glaucoma-Related Retinal Ganglion Cell Apoptosis In Vivo Invest. Ophthalmol. Vis. Sci., February 1, 2006; 47(2): 626 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. H. Yucel, N. Gupta, Q. Zhang, A. P. Mizisin, M. W. Kalichman, and R. N. Weinreb Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Arch Ophthalmol, February 1, 2006; 124(2): 217 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Hare, E. WoldeMussie, R. N. Weinreb, H. Ton, G. Ruiz, M. Wijono, B. Feldmann, L. Zangwill, and L. Wheeler Efficacy and Safety of Memantine Treatment for Reduction of Changes Associated with Experimental Glaucoma in Monkey, II: Structural Measures Invest. Ophthalmol. Vis. Sci., August 1, 2004; 45(8): 2640 - 2651. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
